Vatalanib

Drug Profile

Vatalanib

Alternative Names: CGP 79787; PTK 787; PTK/ZK; vatalanib-succinate; ZK 222584

Latest Information Update: 29 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma; Novartis
  • Developer Novartis
  • Class Antineoplastics; Phthalazines; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Colorectal cancer; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours

Most Recent Events

  • 29 Apr 2008 Discontinued - Phase-I for Ovarian cancer in Germany (PO)
  • 29 Apr 2008 Discontinued - Phase-I for Renal cancer in Germany (PO)
  • 29 Apr 2008 Discontinued - Phase-I for Renal cancer in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top